$Grifols (GRFS.US)$Grifols Receives FDA Approval To Treat Surgical Bleeding In Pediatric Patients With Its Fibrin Sealant Solution Benzinga· 3 mins ago
$Grifols (GRFS.US)$I removed the post because i think the PR was tagged to the wrong ticker by the NEWS OUTLETT! And i want to be more safe and check a bit more!
$Grifols (GRFS.US)$Investing.com -- Shares of Grifols SA (BME:GRLS) (NASDAQ:GRFS) rose on Wednesday after Bloomberg News reported that Brookfield Asset Management (TSX:BAM) is seeking bank backing for up to €9.5 billion in debt to facilitate its potential take-private acquisition of the Spanish pharmaceutical producer
$Grifols (GRFS.US)$Benzinga· 2 mins ago FDA Approves Expanded Label For Grifols' XEMBIFY, The First 20% SCIg For Treatment-Naïve Patients With Primary Humoral Immunodeficiencies; Approval Includes Biweekly Dosing Following Positive Phase 4 Data, Enhancing Flexibility And Convenience For Patients
Morning traders, it is the final slow week before a new earnings season begins Thurday with$Delta Air Lines (DAL.US)$and properly on Friday with$JPMorgan (JPM.US)$. Welcome to the end of the dog days of summer for a while; my name is Kevin Travers, and here are stories from the moomoo herd on Wall Street today. $Intel (INTC.US)$traded higher after the firm said it had bypassed Vietnam for a $3.3B project and in...
$Grifols (GRFS.US)$Grifols' founding family and Canadian fund Brookfield are considering a joint takeover bid of the Spanish drugmaker to take it private, after the company shed billions in market value following a variety of accusations from a short-seller.
$Grifols (GRFS.US)$Grifols Says €1.6 Billion Net Cash Proceeds From Sale Of 20% Equity Stake In Shanghai RAAS Are Currently Deposited In Co's Bank Account; Proceeds Will Be Fully Allocated To Reduce 2025 Senior Secured Notes And 2027 Term Loan B And On A Pro-Rata Basis As Per Credit Agreement; To Repay In Full 2025 Debt Maturities, Leaving No Additional Maturities Until 2027 - Reuters
$Grifols (GRFS.US)$Grifols' Subsidiary Biotest Receives FDA Approval For Yimmugo, An Intravenous Immunoglobulin Therapeutic, To Treat Primary Immunodeficiencies, With US Launch Expected In Second Part Of 2024 Benzinga· 1 min ago
1
1
Report
Trytosaveabit
OP
:
The Spanish pharmaceutical group said Monday it plans to launch the intravenous immunoglobulin therapeutic in the US within the year.
Grifols Stock Forum
Benzinga· 3 mins ago
FDA Approves Expanded Label For Grifols' XEMBIFY, The First 20% SCIg For Treatment-Naïve Patients With Primary Humoral Immunodeficiencies; Approval Includes Biweekly Dosing Following Positive Phase 4 Data, Enhancing Flexibility And Convenience For Patients
Welcome to the end of the dog days of summer for a while; my name is Kevin Travers, and here are stories from the moomoo herd on Wall Street today.
$Intel (INTC.US)$ traded higher after the firm said it had bypassed Vietnam for a $3.3B project and in...
2. $Inspire Veterinary Partners (IVP.US)$
3. $Dynatronics (DYNT.US)$
4. $Zapp Electric Vehicles (ZAPP.US)$
5. $Maxeon Solar Technologies (MAXN.US)$
6. $Grifols (GRFS.US)$
7. $SinglePoint (SING.US)$
8. $Venus Concept (VERO.US)$
9. $IDEAYA Biosciences (IDYA.US)$
10. $Kuke Music (KUKE.US)$
- Reuters
Benzinga· 1 min ago
No comment yet